All In Biotech

Drug Trial Radar · NCT07938632

TL-925 for the Treatment of Allergic Conjunctivitis

A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 100 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis of Both Eyes

Interventions

  • TL-925Drug

    TL-925 is an eye drop.

  • PlaceboDrug

    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Itching ScoreTime frame: Day 2, Day 16 and Day 23
  2. Conjunctival Redness ScoreTime frame: Day 2, Day 16 and Day 23

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.